Rigel Pharmaceuticals Issues New Safety Alert To Healthcare Providers On Key Updates For GAVRETO

A Dear Health Care Provider (DHCP) letter was recently issued by Rigel Pharmaceuticals, Inc., a biotech company specializing in blood disorders and cancer drugs. The public notice is based on a new safety issue concerning GAVRETO® (pralsetinib). It is administered for the treatment of certain cancers, which include metastatic RET fusion-positive non-small cell lung cancer (NSCLC) and advanced RET-fusion-positive thyroid cancer, in scenarios where radioactive iodine therapy is not practical. The letter, developed in collaboration with the FDA, is now available on the GAVRETO Healthcare Provider website at www.gavreto-hcp.com.

Rigel has reaffirmed that patient safety always comes first and promises to continue to keep healthcare providers informed of this most recent safety update. Healthcare providers and patients are advised to report adverse reactions to GAVRETO. Reports can be made through Rigel's Medical Communications Center at 1-800-983-1329 or via email at [email protected]. Additionally, adverse events can be reported directly to the FDA by visiting www.fda.gov/medwatch site or calling 1-800-FDA-1088 (1-800-332-1088).

This notice follows Rigel’s completion of the New Drug Application (NDA) transfer for GAVRETO from Blueprint Medicines Corporation earlier in June 2024.